Last reviewed 2026-04-20 · How we verify

Bemarsal (DIFETARSONE)

Phase 2 active Small molecule

Bemarsal (generic name: DIFETARSONE) is a difetarsone drug. It is currently in Phase 2 development.

Bemarsal works by interacting with a specific cellular target to produce a therapeutic effect.

Bemarsal (difetarsone) is a small molecule drug in the difetarsone class, but its target and commercial status are unknown. Its mechanism of action is not publicly disclosed. As a result, there is limited information available on its approved indications, half-life, bioavailability, generic manufacturers, and off-patent status. Further research is needed to understand the clinical applications and safety profile of bemarsal. Its development and ownership information are also not publicly available.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIFETARSONE
Drug class	difetarsone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine bemarsal as a key that fits into a lock on a cell. When it binds to the lock, it triggers a series of events that ultimately lead to the desired therapeutic outcome. This process can help to modulate the cell's behavior and produce a beneficial response.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bemarsal CI brief — competitive landscape report
Bemarsal updates RSS · CI watch RSS

Frequently asked questions about Bemarsal

What is Bemarsal?

Bemarsal (DIFETARSONE) is a difetarsone drug.

How does Bemarsal work?

Bemarsal works by interacting with a specific cellular target to produce a therapeutic effect.

What is the generic name of Bemarsal?

DIFETARSONE is the generic (nonproprietary) name of Bemarsal.

What drug class is Bemarsal in?

Bemarsal belongs to the difetarsone class. See all difetarsone drugs at /class/difetarsone.

What development phase is Bemarsal in?

Bemarsal is in Phase 2.

Drug class: All difetarsone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing